RedHill Biopharma Ltd. (NASDAQ: RDHL) (Tel-Aviv Stock Exchange: RDHL) is a specialty biopharmaceutical company primarily focused on development and commercialization of clinical late-stage, proprietary drugs for the treatment of gastrointestinal diseases. RedHillâs pipeline includes several drug candidates in advanced clinical development stages addressing clear medical needs and aiming to relieve suffering and save lives. RedHillâs drugs are largely de-risked and are potentially of lower cost and faster to market than new chemical entities under development. RedHillâs products are based on several technology platforms and address several disease targets, thus providing for risk diversification. RedHillâs U.S. commercial operations, headquartered in Raleigh, NC, include a gastrointestinal-focused sales force promoting several specialty gastrointestinal products in select U.S. territories. RedHillâs experienced management team, board of directors and advisory board, based in Israel, the US, Canada and Europe, comes with a successful track record of bringing patented drugs to the market, as well as extensive managerial, financial, and transactional expertise.
Source
